Mitsui Chemicals, Inc. (TSE: 4183) agreed on November 9, 2026 to acquire JSR Corporation at a total acquisition price of ¥1,840Bn on an enterprise-value basis. The figure comprises an equity value of ¥1,392.1Bn for 100% of JSR plus ¥447.9Bn of assumed interest-bearing debt and other items, subject to closing adjustments. The parties disclose yen only; press conversions near ¥158 per dollar imply an approximate $11.6Bn to $12Bn transaction value. The trade press has called it the largest transaction in the history of Japan’s chemical industry.
There is no tender offer. JSR was delisted from the Tokyo Stock Exchange Prime Market on June 25, 2024, so the shares are being bought privately under a share purchase agreement. The seller is the state-backed Japan Investment Corporation (JIC), acting through two limited partnerships managed by its subsidiary JIC Capital, Ltd. (JICC), rather than a public shareholder base. Mitsui Chemicals is acquiring jointly with Development Bank of Japan Inc. (DBJ), which is contributing ¥200Bn of the equity as a co-investor, and closing is targeted for the second half of the fiscal year ending March 2028.

Transaction Overview
The buying group is acquiring 102,242,573 JSR common shares from the two partnerships. JIC PEFJ1 Limited Partnership held 89.72% of the shares and 93% of the voting rights as of March 31, 2026, while JIC PEF1 Limited Partnership held 6.75% and 7%, respectively, and both are selling in full. A separate agreement covers 1,868,933 Class A and 1,868,933 Class B preferred shares, which are expected to convert into common after closing. DBJ’s common shares are expected to convert into non-voting preferred at closing, leaving Mitsui Chemicals with 100% of JSR’s voting rights.
The price is bridged with a ¥1,640Bn loan facility from Mitsui’s principal financial institutions, alongside DBJ’s ¥200Bn of equity. Permanent financing is targeted within about one year after closing, using roughly ¥300Bn of hybrid instruments carrying 50% equity credit for rating purposes and up to ¥150Bn of common share issuance under a shelf registration effective November 17, 2026. Net debt to EBITDA is expected to exceed 4x temporarily, and Mitsui states an aim of restoring an A-range issuer rating. Its investor materials put the enterprise value at approximately 16x EBITDA on an FY2026 outlook of about ¥110Bn, falling to 12x on the full ¥40Bn of targeted synergies.
Strategic Rationale and the Front-End Gap
Mitsui describes the acquisition as a means to accelerate the portfolio transformation required for its group to become a truly global specialty company. President Satoshi Ichimura, speaking in Tokyo on November 9, framed it as establishing a strong presence in the semiconductor materials industry. JSR is to sit at the core of Mitsui’s ICT Solutions domain, with concentrated investment in R&D, people and facilities. ICT Solutions produced ¥36.9Bn of operating income before special items in FY2025 at a 13.2% return on sales, from a product set led by EUV pellicles, SP-PET films and ICROS Tape for back-end dicing and grinding.
Mitsui discloses that only those three product areas exceed ¥10Bn in annual sales. The existing franchise is therefore narrow and weighted toward back-end process steps, which is precisely where JSR’s front-end photoresist position appears complementary. The targets reflect that arithmetic: ICT Solutions with JSR is expected to deliver at least ¥130Bn of operating income before special items in FY2028 at a 20% return on sales, with synergies guided at ¥40Bn by FY2035. Mitsui has also widened its business-separation study from Basic & Green Materials to include Mobility Solutions, which points to part of the funding coming from pruning rather than from leverage alone.
Competitive Positioning in Semiconductor Materials
JSR is an advanced materials company in Minato-ku, Tokyo, with 6,951 consolidated employees as of March 31, 2026. For the fiscal year ended March 2026, it reported revenue of ¥440,718MM, core operating profit of ¥62,348MM and profit attributable to owners of ¥59,329MM. Year-on-year comparisons are not meaningful, because the prior year carried an operating loss of ¥204,434MM on large impairments. Digital Solutions is where the greatest value sits, generating ¥252.1Bn of FY2025 net sales and ¥63.2Bn of operating income before special items at a 25.1% return on sales. Plastics contributed ¥92.8Bn of sales at a 3.7% return.
Mitsui characterizes JSR as the No.2 photoresist supplier globally and the only company offering both chemically amplified and metal-oxide resist platforms for EUV, with the No.1 global share in LCD alignment films. The trade press places Tokyo Ohka Kogyo first in photoresists. JSR’s life sciences unit, a CRO and CDMO business with ¥102.1Bn of FY2025 sales at a 4.8% return, is designated non-core and under evaluation for all options, which makes a divestiture appear more likely than not.
Broader Implications for Japanese Industrial M&A
The seller’s history is the most instructive part of the transaction. JIC announced a tender offer for JSR in June 2023 at ¥4,350 per common share and acquired 175,120,931 shares in an offer that closed on April 16, 2024, taking JICC to 84.36%. A squeeze-out followed before the June 2024 delisting. The common-share consideration computes to roughly ¥762Bn, so an exit at a ¥1,392.1Bn equity value suggests a substantial return on a hold of about two years. JIC states that it received proposals from several operating companies and chose Mitsui Chemicals, with DBJ, on the basis of economic rationality for the fund and synergies for the domestic semiconductor materials industry. It judged the sale would contribute to consolidation.
A state-backed fund took a listed supplier private, held it for roughly two years and is now selling it into domestic consolidation rather than to an overseas buyer. That sequence suggests how Japan approaches ownership of critical materials assets, and it is JIC Capital’s second sizable semiconductor transaction in close succession, after the Shinko Electric Industries take-private completed in March 2025. The approvals runway is the principal execution risk the parties themselves flag, described in their own wording as necessary procedures under competition law and foreign investment regulations in Japan and overseas, with no jurisdiction named. JIC postponed the start of its own JSR tender offer in December 2023 because a Chinese competition review was unfinished, and that offer did not open until March 19, 2024.
Conclusion
Mitsui Chemicals is paying ¥1,840Bn for a business with roughly ¥441Bn of revenue, against its own market capitalization of about ¥664.6Bn before announcement, as compiled by trade press. That puts the enterprise value at roughly 2.8 times the acquirer’s equity value, and the structure shows the stretch, with a ¥1,640Bn bridge, leverage temporarily above 4x and an equity shelf already in place. The price buys the front-end photoresist franchise that Mitsui’s narrow, back-end-weighted semiconductor portfolio has lacked. Pending clearances and with closing targeted for the second half of the fiscal year ending March 2028, the transaction stands on the terms disclosed on November 9.
About DelMorgan & Co. (www.delmorganco.com)
With over $300 billion of successful transactions in over 80 countries, DelMorgan’s Investment Banking professionals have worked on some of the most challenging, most rewarding and highest profile transactions in the U.S. and around the globe. DelMorgan specializes in capital raising and M&A advisor services for companies across all industries and is recognized as one of the leading investment banking practices in California and globally.
Learn more about DelMorgan’s Capabilities, Transactions, and why DelMorgan is ranked as the #1 Investment Bank in Los Angeles and #2 in California by Axial.








